HKSTP
6.9.2021 10:00:09 CEST | Business Wire | Press release
Hong Kong Science and Technology Parks Corporation (HKSTP) has formally kickoff the Elevator Pitch Competition 2021 (EPiC 2021) by inviting applications from tech ventures in Hong Kong around the world. Taking place from 5 to 12 November, 2021, participating entrepreneurs can join their peers, investors and innovation eco-system leaders in an international week-long fest of pitching, investment and business matching as well as learning from icons in the startup landscape.
Companies and individuals are invited to EPiC 2021, which is in its sixth year and taking place for the first time as a hybrid event – a dynamic physical and virtual platform to meet the diverse needs of overseas and local innovators. To celebrate HKSTP’s 20 years of leading Hong Kong innovation, the event will return to its iconic SKY100 venue at the top of International Commerce Centre in West Kowloon to re-create a genuine elevator pitch experience.
Over 100 contestants will be shortlisted for the opportunity of competing in the hybrid event where physical attendees deliver a signature 60-second elevator pitch for their world-changing ideas, while virtual participants will make their pitch to our judges via video call. A further ten finalists will be selected to compete for the winning cash prize of US$100,000 as well as unique opportunities for cross-border investment, business collaboration and technology development and adoption.
The international week-long festival of investment and innovation will focus on high-potential ideas in FinTech, Health Technology, Smart City, and the emerging area of Green Tech & Construction Tech.
Robert Luo, CEO and Co-founder of 2020 champion winner MiTerro from the US, said: “Winning EPiC was a validation of our business and vision. We not only met investors but also other entrepreneurs who are finding innovative solutions to some of the world’s biggest problems.”
HKSTP is committed to acting as a bridge between innovators and investors, with HKSTP nurturing over 500 start-up companies and connected them to more than 1000 active investors. All winners from the competition can proceed to leverage the full resources of the HKSTP ecosystem for investment, incubation, market access, technology, and partnership opportunities.
The competition attracted a record number of 476 entries from 37 countries around the globe in 2020. Over 70% of the 170 contestants reaching the semi-final round were from 31 international markets. The event brought more than 1,000 entrepreneurs, venture capital firms, angel investors, industry players, incubators, accelerators and tech disruptors together, to showcase the growing strength of the I&T ecosystem in Hong Kong.
Who can apply:
- Tech startups that are less than five years old and have received less than US$10 million in funding by 31 March 2021 OR individuals who have not yet established any companies
- Ideas should focus on one of the four technology areas: FinTech, Health Technology, Smart City, and Green Tech & Construction Tech.
Applications will close on 10 September 2021, at 23:59 hrs, Hong Kong time.
Please visit https://epic.hkstp.org/ for more detailed information on EPiC 2021.
List of awards and prizes
Award |
Cash Prize
|
Champion |
US$100,000 |
4 Tech Winners
|
US$10,000 |
Top 10 Finalists |
US$6,000 |
About Hong Kong Science and Technology Parks Corporation
Comprising Science Park, InnoCentre and Industrial Estates, Hong Kong Science & Technology Parks Corporation (HKSTP) is a statutory body dedicated to building a vibrant innovation and technology ecosystem to connect stakeholders, nurture technology talents, facilitate collaboration, and catalyse innovations to deliver social and economic benefits to Hong Kong and the region.
Established in May 2001, HKSTP has been driving the development of Hong Kong into a regional hub for innovation and growth in several focused clusters including Electronics, Information & Communications Technology, Green Technology, Biomedical Technology, Materials and Precision Engineering. We enable science and technology companies to nurture ideas, innovate and grow, supported by our R&D facilities, infrastructure, and market-led laboratories and technical centres with professional support services. We also offer value added services and comprehensive incubation programmes for technology start-ups to accelerate their growth.
Technology businesses benefit from our specialised services and infrastructure at Science Park for applied research and product development; enterprises can find creative design support at InnoCentre; while skill-intensive businesses are served by our three industrial estates at Tai Po, Tseung Kwan O and Yuen Long. More information about HKSTP is available at www.hkstp.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20210906005047/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom